ZA200109793B - Steroid derivatives. - Google Patents
Steroid derivatives. Download PDFInfo
- Publication number
- ZA200109793B ZA200109793B ZA200109793A ZA200109793A ZA200109793B ZA 200109793 B ZA200109793 B ZA 200109793B ZA 200109793 A ZA200109793 A ZA 200109793A ZA 200109793 A ZA200109793 A ZA 200109793A ZA 200109793 B ZA200109793 B ZA 200109793B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- sulfonic acid
- compound
- hydroxy
- amino
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title description 80
- 125000000217 alkyl group Chemical group 0.000 claims description 127
- 150000001875 compounds Chemical class 0.000 claims description 94
- -1 amino, carboxyl Chemical group 0.000 claims description 83
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 63
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- 239000001257 hydrogen Substances 0.000 claims description 62
- 125000003342 alkenyl group Chemical group 0.000 claims description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 38
- 125000004043 oxo group Chemical group O=* 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 28
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 16
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 15
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 15
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 15
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 125000004414 alkyl thio group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 47
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 43
- 239000000126 substance Substances 0.000 claims 14
- 125000004429 atom Chemical group 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 description 30
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 23
- 125000005843 halogen group Chemical group 0.000 description 22
- 238000003556 assay Methods 0.000 description 20
- 101000603962 Homo sapiens Oxysterols receptor LXR-alpha Proteins 0.000 description 19
- 102100038476 Oxysterols receptor LXR-alpha Human genes 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 14
- 102000006255 nuclear receptors Human genes 0.000 description 14
- 108020004017 nuclear receptors Proteins 0.000 description 14
- 108060001084 Luciferase Proteins 0.000 description 12
- 239000005089 Luciferase Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 108090000865 liver X receptors Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 108020001756 ligand binding domains Proteins 0.000 description 8
- 102000004311 liver X receptors Human genes 0.000 description 8
- 102100039556 Galectin-4 Human genes 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 108091027981 Response element Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 5
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 5
- 108700010039 chimeric receptor Proteins 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 4
- 108010001515 Galectin 4 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001086 yeast two-hybrid system Methods 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 101150050070 RXRA gene Proteins 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 102100038595 Estrogen receptor Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101100055553 Homo sapiens AR gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229960001445 alitretinoin Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000027507 nuclear receptors type II Human genes 0.000 description 2
- 108091008686 nuclear receptors type II Proteins 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000008196 pharmacological composition Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- GPUVTXKHQDYRQO-YFQQQAHJSA-N (8r,9s,10s,13s,14s,17r)-17-ethyl-17-hydroxy-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](CC)(O)[C@@]1(C)CC2 GPUVTXKHQDYRQO-YFQQQAHJSA-N 0.000 description 1
- JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 description 1
- YPEARZUTWVZHIZ-SRJHXTLLSA-N 1-[(8r,9s,10s,13s,14s,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanol Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(O)C)[C@@]1(C)CC2 YPEARZUTWVZHIZ-SRJHXTLLSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010020650 COUP Transcription Factor II Proteins 0.000 description 1
- 102100028226 COUP transcription factor 2 Human genes 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 1
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 1
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- 101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000046818 human AR Human genes 0.000 description 1
- 102000056666 human NR1H3 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 108091006058 immobilized fusion proteins Proteins 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002718 inhibitory effect on inflammation Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- BWDRDVHYVJQWBO-FOVVUBNDSA-N methyl (4r)-4-[(3r,6s,8s,9s,10r,13r,14s,17r)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound C1([C@@H](O)C2)C[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCC(=O)OC)[C@@]2(C)CC1 BWDRDVHYVJQWBO-FOVVUBNDSA-N 0.000 description 1
- HDDPSAANGLHNKP-XUKJWFLHSA-N methyl (4r)-4-[(6s,8s,9s,10r,13r,14s,17r)-6-hydroxy-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound C1([C@@H](O)C2)CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCC(=O)OC)[C@@]2(C)CC1 HDDPSAANGLHNKP-XUKJWFLHSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
: STEROID DERIVATIVES
Nuclear receptors are a family of transcription factors modulated by small hydrophobic signaling molecules, like steroids, thyroid hormone, free fatty acids, vitamin D and retinoids. Nuclear receptors are important pharmacological targets for drug intervention in disease management. For example, Tamoxifen, an estrogen antagonist, interacts with estrogen receptor to deliver its therapeutic effects on breast cancer; RU486, an antagonist of progesterone receptor, is used for termination of pregnancies and menopause-related disorders; and
Dexamethasone interacts with glucocorticoid receptor to suppress immune system function and is useful for treating inflammatory diseases such as asthma.
Nuclear receptors have three independent domains I, II and III. Domains
I and III modulate transcriptional activities by interacting with other factors of the transcription complex; Domain II involves in DNA-binding; and Domain III is the ligand-binding domain. Domain II is the most conserved region within the nuclear receptor family, with a unique feature of four pairs of cysteine chelated with two zinc atoms which form a "zinc finger" structure. The three domains of nuclear receptors are functionally interchangeable between different members.
For example, the androgen receptor DNA-binding domain can be fused to the ligand-binding domain of estrogen receptor and the resulting AR-ER chimeric receptor can modulate androgen-responsive genes by binding to estrogen.
Amino acid sequence homology of the DNA-binding domain between members of nuclear receptor family allows identification of new members of this family through low stringency nucleotide-probe screening. Human genome project also facilitates identification of new genes coding for new nuclear receptors. At present, a few dozens of nuclear receptors have been identified and sequenced, but their ligands have yet to be identified. Recently, a novel nuclear receptor was cloned through degenerate oligonucleotide screening from human and rat cells and was named ubiquitous nuclear receptor ("UR"), because of its ubiquitous expression pattern in the body. UR has been found to form heterodimers with RXR receptors and binds to double-stranded DNA with the sequence motif: AGGTCANNNNAGGTCA (SEQ ID NO: 1) ("DR4").
Promoters containing DR4 can be activated by UR and RXR heterodimer in cultured cells.
LXRa, another new member of the nuclear receptor family has been cloned recently. Amino acid sequence analysis revealed that it sharcs over 80% homology with UR in the DNA- and ligand-binding domain. ‘The expression of
LXRa mRNA is limited to liver and a few other tissues. LXRa has been identified as a transcriptional activator of the cholesterol 7a-hydroxylase gene and plays an important role in cholesterol] catabolism.
Recently other nuclear proteins interacting with nuclear receptors have been identified through yeast two-hybrid screening techniques, among which are co-activators and co-repressors of nuclear receptors, e.g., SRC1, 2, 3, and Grip.
These proteins interact with nuclear receptors in a ligand-dependent manner.
This property is useful to set up biochemical assays for ligand-receptor teraction.
Steroid derivatives described in this invention are found to modulate the transcriptional activities via binding to UR or LXRa, and thus can be used to treat disorders mediated by such receptors such as atherosclerosis.
An aspect of this invention relates to steroid derivatives of formula (1): 17 ,
R12 R R! 7 13 rR R R16 rR! ) 1] RO | R& 6)
R 15 14 R
R n
R3 R’
RS
R* R* R°®
Ris hydrogen, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or - alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO;-, -O-
S0,-, -S0,-0-, -0-80;-, -S0;-0-, -CO-, -CO-0-, -0-CO-, -CO-NH-, -CO-
N(alkyl)-, -NH-CO-, or -N(alky1)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or ~O-sulfonic acid. Each of R',
R*, RL, RY, R% R7,R", RZ, RS, R", and R'7, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that 1s optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO5-, -0-S0,-, -SO,- 0-, -0-80;3-, -S03-0-, -CO-, -CO-0-, -0-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-
CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or ~O-sulfonic acid. Each of R®, Rf, R’, RR" R and R'*, independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino. R'’ is -X-Y-Z. X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R'” are bonded. Y is
-CO-, -80-, -80;-, -0-S0;-, -S0,-0-, -0-503-, -503-0-, -CO-0-, -0-CO-, -CO-
NH-, -CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond. Z is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, : alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl; or alkylthio; or is -CH(A)-B. A being a side chain of an amino acid, and B is hydrogen, -NR’R®, or -COOR® wherein each of R?, R®, and R°, independently, is hydrogen or alkyl. nis 0, 1, or 2. Note that when Z is substituted with carboxy! or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y is 2 bond, either
X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyi-, -N(alkyl)-alkenyl-, -O-alkyl-, -
O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -
O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl, or is alkenyl. a 15 Another aspect of this invention relates to steroid derivatives having the formula (I) as depicted above. Each of R, RZ, R3, R*, RY, R®, R’, R! l R'?, RY,
RS and R!", independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic actd, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -
N(alkyl)-, -O-, -S-, -SO-, -SO»-, -0-80;-, -S0,-0-, -0-S0;-, -$03-0-, -CO-, -
CO-0-, -0-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alky1)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid. Each of R®, R®, R’, R"’, R" and R", independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino. R'is -X-
Y-Z. X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -
O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R'” are bonded. Y is -CO-, -SO-, -SO;-, -0-SO,-, -S0,-0-, -0-803-, -S03-0-, -CO-0-, -0-CO-, -CO-NH-, -CO-N(alky!)-, -NH-
CO-, -N(alkyl)-CO-, or abond. Z is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, - sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio; or is -CH(A)-B.
A is an amino acid side chain containing an aromatic moiety, and B is hydrogen, -NR°R®, or -COOR® wherein each of R? R®, and R, independently, is hydrogen or alkyl. n is 0, 1, or 2. Note that when Z is substituted with carboxy] or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl- , “O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfony}, or is alkenyl.
A further aspect of this invention relates to steroid derivatives of formula (1), supra. Each of R', R%, R, RY, R*, R® R7,R'', R"2, R** R' and R'7, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -
O-sulfonic acid, or alkyl optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -S0O;-, -O-S0;-, -SO,-0-, -0-503-, -S03-0-, ~~ -CO-, -CO-0-, -0-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid. Each of R®, RS, rR’, RY R" ,and R", independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino. R'is -X-
Y-Z. X is abond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -
O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R" are bonded. Y is
-CO-, -80-, -80;-, -0-S0,-, -S0;-0-, -0-803-, -S0;3-0-, -CO-0-, -0-CO-, -CO-
NH-, -CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond. Z is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl. heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or atkylthio; or is -CH(A)-B. Aisa side chain of an amino acid, and B is hydrogen, -NR°R®, or -COOR® wherein each of R?, R®, and R°, independently, is hydrogen or alkyl. nis 0, 1, or 2. Note that when Z is substituted with carboxyl or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either
X'is -NH-alky!-, -NH-alkenyl-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl-, -O-alkyl-, -
O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -
O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl, or is alkenyl; and that at least one of R* and R%, R* and R®, R® and R®, R” and R®, R"? and R", and RS and R'®, independently, is deleted to form a double bond. One subset of the just-described steroid derivatives encompasses compounds which are featured by the presence of at least one double bond in the rings, which are formed by deleting one or more of the following pairs of substituents: R* and R*, R* and R*, R'? and R"?, and R'"* and R'®. Another subset encompasses compounds which are featured by that Z is alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and optionally substituted with hydroxy, alkoxy, amino, or halo; or is -CII(A)-B. A and B are as described above.
Note that X and Z optionally join together to form a cyclic moiety. For example, if both X and Z are alkyl, and Y is -C(=0)-0O-, a lactone results from joining X and Z.
A salt of the steroid derivative of this invention is also within the scope of this invention and can be formed. for example, between the steroid of this invention having a carboxylate and a cationic counterion such as an alkali metal cation, e.g., a sodium ion or a potassium ion; or an ammonium cation that can be substituted with organic groups, e.g., a tetramethylammonium ion or a diisopropyl-ethylammonium ion. A salt of this invention can also form between the steroid derivative of this invention having a protonated amino group and an anionic counterion, e.g., a sulfate ion, a nitrate ion, a phosphate ion, or an acetate - ion. : -
Set forth below are some examples of steroid derivatives of this invention:
Ar
COOMe o— : o—
NS (2) Fo] 0 x
O
H HO 0 HO
H H 5H \
N—
QO, —COOH eS ; 4) H (6) [@] (5) iY lo)
H H
HO fo) [e]
OH
Q ~ 0 OH A
NH 8) (7 ..-OH 9)
OH OH
HO’ lo] HO \ 1)
CH,CI wa, HN— 2 (10) COOMe 0 o (ny
HO : HO”
H &H H OH
CF, COOH o) 13 (12) (13) (14)
HO" y Hi HO
H OH
- a =
CONH, / $ (16) (17) (15)
HO3SO HO” |):
HO OH re HO,S0
COOH \ (18) ae A (19)
H
HO HO
CH,CI oF
Hv—/ 3 int (¢2)] x lo) $ (23) (22) lo) Y © H 6H © .
HoH H bn
OH F
° © (25) (24) (26)
H HO Hi
H . / / 27 (28)
HO .
HO
OH
F
H J
7% 29) (30) . HO OH to
OH
/ and an
HO Y
3 OH
As used herein, the term "alkyl" in this disclosure denotes a straight or branched hydrocarbon chain containing 1-8 carbon atoms. Some examples of an alkyl group are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, or 2-methylpentyl. By the term "cycloalkyl" is meant a cyclic hydrocarbon chain that has 3-8 carbon atoms. The cycloalkyl groups herein described may also contain fused rings. Fused rings are rings that share a common carbon-carbon bond. Examples of cycloalkyl groups include, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and norbormyl.
The term "alkenyl" refers to a straight or branched hydrocarbon chain containing 2-8 carbon atoms and characterized in having one or more double bonds. Examples of a typical alkenyl include, but not limited to, allyl, propenyl,
2-butenyl, 3-hexeny! and 3-octenyl groups. The term "cycloalkenyl" is meant a cyclic hydrocarbon chain containing 3-8 carbon atoms and having at least one or more double bonds. Similar to the defmition of cycloalkyl groups above, cycloalkenyl groups may also contain fused rings. Some examples of cycloalkenyl groups are cyclopentenyl, cyclohexenyl, cycloheptenyl, norbornylenyl, and cyclooctenyl groups.
The term "alkynyl" refers to a straight or branchéd hydrocarbon chain containing 2-8 carbon atoms and characterized in having one or more triple bonds. Some examples of a typical alkynyl are ethynyl, 2-propynyl, and 3- methylbutynyl.
The terms "heterocycloalkyl” and "heterocycloalkeny!" refer to cycloalkyl and cycloalkenyl groups which contain one or more heteroatoms, such as, nitrogen, oxygen, or sulfur. Typical heterocycloalkyl and heterocycloalkenyl groups include tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholino, pyrrolinyl and pyrrolidinyl. "Aryl" represents an aromatic moiety which contains 6-12 carbon atoms and can contain fused rings. A fused ring is an aromatic group which contains at
E least two aryl rings sharing a common carbon-carbon bond. Typical examples of : aryl include phenyl and naphthyl. oy 20 "Heteroaryl" groups in this disclosure are aromatic groups containing 5 to 12 ring atoms, in which one or more of these ring atoms are heteroatoms as defined above. Some examples of heteroaryl groups are pyridyl, pyrazinyl, furyl, pyrrolyl, thienyl, thiazolyl, benzimidazolyl, and imidazolyl.
The positions of substituents on each of the cyclic groups described herein may be at any available position, unless specified otherwise. For example, a methyl substituent on a benzene ring can be attached at the ortho, meia, or para position.
The term "alkoxy" is defined as the moiety "-O-alkyl." Some examples are methoxy, ethoxy, propoxy, isopropoxy, and t-butoxy. "Halo" represents a halogen atom, such as, fluoro, chloro, bromo, or iodo. By the terms "haloalkyl" and "hydroxyalkyl" are meant alkyl groups which are respectively substituted with one or more halogen atoms and one or more hydroxy groups. The nitrogen atom in an amino or amido group present in a steroid derivative of this invention can be mono- or di-substituted with an alkyl, a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl. : For convenience, a divalent moiety is named herein as if it were a monovalent moiety. For example, "alkyl," such as CHa, which is assigned to X, actually stands for "alkylene," such as -CH,;-. As recognized by a skilled person in the art, steroid derivatives described herein contain stereocenters. Both the racemic mixtures of isomers and the optically pure isomers are within the scope of this invention.
Yet another aspect of this invention relates to a pharmaceutical composition for treating a UR- or LXRa-mediated disorder which contains a pharmaceutically acceptable carrier and an effective amount of one or more of the steroid derivatives described above. The use of such a steroid derivative or a salt . thereof for the manufacture of a medicament for treating the above-mentioned disorders is also within the scope of this invention.
A still further aspect of this invention relates to a pharmacological composition for treating cancer, including solid tumors and leukemia, and immune dysfunction. The pharmacological composition contains a pharmaceutically acceptable carrier and an effective amount of one or more of a steroid derivative of formula (I), supra. Each of R', R?, R?, R*, R*, R, R",R",
RZ? RY R', and R", independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyD)-, -O-, -§-, -SO-, -SO;-, -0-S0;-, -S0,-0-, -0-S0;-, -S0;-0-, -
CO-, -CO-0-, -0-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or —~O-sulfonic acid. Each of RS, RS, rR’, R'® R" ,and R", independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino. Ris -X-
Y-Z, in which X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -
N(alkyl)-, -O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R!” are bonded; Y is -CO-, -SO-, -SO,-, -0-50;-, -S0,-0-, -0-803-, -§03-0-, -CO-0-, -O-CO-, -CO-NH-, -CO-N(alkyl)- , -NH-CO-, -N(alkyl)-CO-, or a bond; and Z is alkyl, alkenyl, alkynyl, cycloalkyl, : heterecycloalkyl, cycloalkenyl, heterocycloatkenyl, aryl, heteroaryl; aralkyl, or - heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio; or is -CH(A)-B with A being a side chain of an amino acid, and B being hydrogen, -NR?R®, or -COOR® wherein each of R? R®, and R¢, independently, is hydrogen or alkyl; and nis 0, I, or 2. When Z is substituted with carboxyl, Y is a bond and either X or Z contains at least one double bond, and when Y is a bond, either X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyl-, -
N(alkyl)-alkenyl-, -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl, or is alkenyl. The use of a just-described steroid derivative or a salt thereof for the manufacture of a medicament for treating the above- mentioned disorders is also within the scope of this invention.
Still another aspect of the present invention relates to a method of treating a UR- or LXRa-mediated disorder by administering to a patient in need thereof an effective amount of one of the pharmaceutical compositions decribed above. - Some examples of UR- or LXRa-mcdiated disorders are: liver cirrhosis, gallstone disease, hyperlipoproteinemias, Alzheimer's disease, anemia, chronic inflammatory diseases (e.g., rheumatoid arthritis), metabolic disorders (e.g., diabetes), and cancers which are associated with UR expression, e.g., breast cancer, colon cancer, prostate cancer, and leukemia. Patients with other disorders such as atherosclerosis and liver cholestasis can also be treated with one of the - pharmaceutical compositions described above.
Other features or advantages of the present invention will be apparent from the following detailed description of several embodiments, and also from the appending claims.
A steroid derivative of this invention can be prepared by forming an amide bond between a steroid having a C17 carboxyl-containing substituent and an amino-containing compound or between a steroid having a C17 amino- . containing substituent and a carboxyl-containing compound. Similarly, an ester bond can be formed between a steroid with a C17 carboxyl-containing substituent and a hydroxyl-containing compound, or between a steroid with a C17 hydroxyl- ; containing substituent and a carboxyl-containing compound. Some examples of a steroid that can be used as a starting material are cholic acid (c.g, ursodeoxycholic acid, hyocholic acid, and hyodeoxycholic acid), androstan-17- : carboxylic acid (e.g., androstan-3-oxo-17-carboxylic acid and d5-androsten-3-ol- 17-carboxylic acid) and pregnan-20-ol (e.g., d5-pregnen-3,17-diol or pregnan-17- ol-3-one). Synthesis of these steroids can be found in the literature, e.g., Roda A. etal, F. Lipid Res. vol. 35, pages 2268-2279 (1994) and Roda A. et al., Dig. Dis.
Sci. vol. 34, pages 24S-35S (1987). Some examples of compounds that can be used to couple to a steroid to form a steroid derivative of this invention are aniline, glycine, phenylalanine, or benzoic acid. Examples of a coupling reagent that can be used in the amide- or ester-forming reaction include 1-ethyl-3-[3- dimethylaminopropyl]-carbodiimide (EDC), dicyclohexyl-carbodiimide (DCC),
N-hydroxybenzo-triazole (HOB), 2-(1H-benzotriazole-1-yl)-1,1,3,3- tetramethyluronium hexafluoro-phosphate (HBTU), or benzotriazole-1-yl-oxy- tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP). The amide- or ester-forming reaction can take place in any solvents that are suitable with the starting materials and reagents. Note that if the reaction takes place in an aqueous solvent, e.g., a buffered solution (or in combination with other miscible organic solvents such as alcohol), isolation of the steroid product for in vitro or in
Vivo screening assays is not necessary, as the product is already in suitable assaying conditions, i.e., in an aqueous buffered medium. Protection of functional groups, €.g., hydroxyl or keto, on the steroids is not needed. See, e.g.,
Example 1 below. Due to the simplicity of the reaction, it can be easily automated. Isolation and quantification of the product can be done by thin-layer chromatography, high pressure liquid chromatography, gas chromatography, capillary electrophoresis, or other analytical and preparative procedures.
Trifluoromethyl- and taurine-conjugated steroid derivatives can be prepared according to methods described in Li, S. et al, Chem. Phys. Lipids 99:33-71 (1999) and Kurosawa, T. et al., Steroids, 60:439-444 (1995), respectively. As to the preparation of 3f-hydroxy-5-cholesten-25(R)-26-carboxylic acid derivatives, see Kim, H. et al., J. Lipid Res. 30:247 (1989) and Varma, R. K. et al,, J. Org.
Chem. 40:3680 (1975). Steroid derivatives having a side chain that contains a double bond, e.g., between C24 and C25, can be prepared according to the following scheme:
o— OH
HO TBDMSO TBOMSO etl | +58”
TBOMSO TBOMSO or’ or’
VERN 7 (24)
TBOMSO HO
OH
J [s]
TBDMS = t-butyl-dimethylsilyl (25)
HO
3-beta-t-butyldimethylsilyloxy-delta[5}-cholen-24-al and 3-alpha,6-alpha- di(t-butyldimethylsilyloxy)5-beta-cholan-24-al were prepared using NaBH4 and pyridinium chlorochromate according to methods described in Somanathan et al.,
Steroids 43:651-655 (1984). Ethyl-3-beta-t-butyldimethylsilyloxy-delta[5,24]- cholestenoate and ethyl-3a,6a-di(t-butyldimethylsilyloxy)-delta[24]-cholestanoate were then prepared via Wittig-Homner reaction using triethyl 2-phosphono- ) propionate and a suitable base according to methods described in Lund et al.,
Arterioscler. Thromb. Vasc. Biol. 16:208-212 (1996). After the t-
butyldimcthylsilyloxyl groups were removed, ethyl ester groups were hydrolyzed under alkaline conditions.
As mentioned above, a pharmaceutical composition containing a steroid derivative or a salt of this invention in an effective amount can be used to treat
UR- or LXRa-mediated disorders. Also within the scope of this invention is a method of treating a UR- or LXRa-mediated disorder such as astherosclerosis by administering to a patient such a composition. An effective amount is-defined-as the amount of the derivative which, upon administration to a patient in need, confers a therapeutic effect on the treated patient. The effective amount to be administered to a patient is typically based on body surface area, patient weight, and patient condition. The mterrelationship of dosages for patients (based on milligrams per meter squared of body surface) is described by Freireich et al,
Cancer Chemother. Rep. 1966, 50, 219. Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables,
Geigy Pharmaceuticals, Ardley, New York, 1970, 537. An effective amount of a compound of this invention used to practice the invention can range from about 1 mg/kg to about 2 g/kg, e.g., from about 1 mg/kg to about 1 g/kg, or from about 1 mg/kg to about 500 mg/kg. Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments.
The pharmaceutical composition may be administered via the parenteral route, including subcutaneously, intraperitoneally, intramuscularly and intravenously. Examples of parenteral dosage forms include aqucous solutions of the active agent, in a isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds.
The steroid derivatives of this invention can also be formulated into dosage forms for other routes of administration utilizing well-known methods.
They can be formulated, for example, in dosage forms for oral administration in a gel seal, a syrup, a capsule, or a tablet. Capsules may comprise any well-known pharmaceutically acceptable material such as gelatin or cellulose derivatives.
Tablets may be formulated in accordance with the conventional procedure by compressing mixtures of the compound of this invention and a solid carrier, and a lubricant. Examples of solid carriers include starch and sugar bentonite. The steroid derivatives of this invention can also be administered in a form of a hard shell tablet or a capsule containing a binder (e.g., lactose or mannitol) and a conventional filler.
The level of interaction between the UR or LXRa protein and a steroid derivative of this invention can be preliminarily evaluated using various assays as described below: . Protease protection assay is a simple assay for measuring the level of . interaction between a test steroid and the UR or LXRa protein. This assay can be . 15 done by using a **S-Met radiolabeled rat UR or human LXRa protein. The radiolabeled protein is then incubated with the steroid of this invention and digested with a protease, e.g., trypsin. A control experiment is done by incubating UR receptor with a protease but without the steroid. Protein fragments from both assays are electrophoresed on a polyacrylamide gel. The fragments from each of the assays can be visualized by exposing the gel to X-ray films and compared side-by-side. A test steroid, if binds to the UR or LXRa protein, will protect the receptor from being digested by the protease. As a result, reactions that result in binding between the steroid and UR will lead to fewer bands of low molecular weights than those that do not result in binding between the two molecules.
The co-activator binding assay employs a fusion protein formed between a glutathione S-transferase (GST) and a co-activator of UR, e.g., Gripl. The
GST moiety of the fusion protein binds to a glutathione-coated solid support, thereby immobilizing the fusion protein. UR and a steroid of this invention are then incubated with the immobilized fusion protein. Subsequently, any bound:
UR is released and collected from the solid support. The proteins are then electrophoresed on a polyacrylamide gel and visualized by exposing the gel to
X-ray films. If the steroid interacts with UR, less UR will bind to the fusion protein, and a lighter band would therefore result on the gel. By monitoring the intensity of the band of the bound UR, one can estimate the binding of the steroid ooo to URS To - Co Te
Yeast two-hybrid binding assay is a sensitive assay for identifying UR modulating compounds by monitoring transcriptional activation. General descriptions of these assay can be found in, e.g., Chien C. T. et al., Proc. Natl.
Acad. Sci. USA, vol. 88, 9578-9582 (1991); Fields, S. et al., Nature, vol. 340, 245-247 (1989); and Green, M. B. et al., Curr. Biol., vol. 2, 403-405 (1992). In : this screening method, a steroid of this invention that modulates the interaction of = UR or LXRa with its natural ligand will have an effect on the transcriptional - 15 activation of a reporter gene. In a specific assay, two plasmids are introduced : into a yeast cell. One expresses a fusion protein having a GAL4 DNA binding domain and a UR natural ligand, and the other expresses a fusion protein containing a UR ligand binding domain and a GAL4 activation domain. If the : - steroid interacts with UR and disrupts the binding of UR to its natural ligand, the i 20 activity of the reporting gene (Gal4) will be altered. The changes in reporter activities (i.e., B-galactosidase activities) can be measured with a commercial luminescence kit.
Mammalian cell transfection can also be used to screen steroid derivatives that affect the interaction between the UR protein and a steroid of this invention.
A rat UR or human LXR gene and a human RXRa gene are cloned into a mammalian expression vector (e.g., pSG5 from Strategene) and overexpressed.
A heterologous promoter is formed by inserting four tandem repeats of a hormone response element DR4 into the vector upstream to a c-fos promoter sequence, which is followed by a sequence encoding luciferase. The entire construct is named DR4-fos-luc. DR4- fos-luc is then co-transfected with pSG5/f'UR or CMV/hLXR and pSG5/hRXRa into mammalian cells, e.g., COS-1 cells. An ethanol solution containing a steroid of this invention is then added to the transfected cells. The steroid, if interacts to the UR or LXRa protein, affects the level at which the luciferase gene is activated. The cells are then lysed and assayed for luciferase activity with a commercial assay kit and a luminometer. A high intensity of luminescence indicates that the steroid is a potent UR or LXR . agonist.
Another chimeric receptor that can be used in this assay is constructed by fusing oligonucleotides encoding the ligand-binding domain of rat UR to a human AR gene lacking ligand-binding site coding region. For this chimeric - receptor, a reporter gene ARE-fos-luc is constructed by inserting three tandem repeats of Androgen Response Element (ARE) into the vector upstream to a c-fos promoter which is followed by a luciferase reporter gene. After adding a steroid of this invention to the medium of the transfected cells, the steroid can interact with UR and affect the level of activation of ARE-fos-luc in cultured cells. The level of luminescence activity thus indicates the level of UR modulation by the steroid.
Yet another assay involves expressing rtUR gene in PC-3 cells by retroviral infection. See Underwood et al., J. Biol. Chem., vol. 273, pages 4266- 4274 (1998). The transfected cells are then seeded in media containing delipidated serum and then treated with a solution containing a steroid of this invention. The PC-3 cells are later washed with phosphate buffered saline (PBS) and treated with 100 mg/ml amphotericin B in DMEM media without serum at 37EC. Amphotericin B functions to kill cells containing cholesterol in the cell membrane. The cells are then fixed in 10% TCA and stained with
Sulforhodamine B after more washing. Viable cells are stained and can then be assessed using a colorimetric assay. The amount of dye is directly proportional to number of surviving cells on the culture plates. From comparing the number of viable cells between assays with and without a steroid, one can estimate the effect the steroid has on the de novo synthesis of cholesterol.
A still further assay makes use of nitrogen monoxide (NO) as an indicator of the level of inflammation. Cells from a murine macrophage cell line
RAW264.7 are incubated with a steroid of this invention for 24 hours. The macrophages are then activated by adding lipopolysaccharide (LPS) and gamma-interferon. The NO production-of activated macrophages can be : monitored indirectly by quantifying NO2 in the media according to Green L. et al., Anal. Biochem., vol. 126, 131-138 (1982). The reduced amount of NO in comparison to that of a control experiment in which no steroid is used indicates that the steroid used in the assay has inhibitory effect on inflammation.
Using the same murine macrophage cell line RAW264.7, constitutive expression of rat UR and human RXRa gene by retroviral systems transforms . these cells into foam-cell-like morphology and integrated into clumps while increasing cell sizes and undergo apoptosis. Foam cells originated from : macrophages are the major components in pathological plaque which is usually found on the inner wall of blood vessels in patients suffering from atherosclerosis. Steroid derivatives of this invention which modulate UR can : suppress the progression of macrophage-foam cell transformation at different . 20 stages, and can be used in the treatment or prevention of atherosclerosis. See
Kellner-Weibel et al., Arterioscler. Thromb. Vasc. Biol, vol. 18, pages 423-431 (1998).
Yet another assay measures the effect of a steroid of this invention has on the level of adipocyte differentiation on fibroblasts. Specifically, the level of adipocyte diffcrentiation in murine fibroblasts 3T3-L1 containing rat UR gene at sub-confluent conditions is measured. Constitutive expression of rat UR gene in murine fibroblasts 3T3-L1 can be done by using retroviral systems. Full-length rat UR cDNA are inserted into retroviral expression vector MV7. Infected 3T3-L1 cells that are G418- resistant are treated with insulin, dexamethacine, and
1- methyl-3-isobutyixanthine (MIX) to induce adipocyte differentiation. A control experiment can be done by inserting human UR ¢cDNA into MV7 in the antisense orientation. Cells infected with hUR-antisense constructs and parent 3T3-L1 cells are also treated with the same insulin cocktail under same cell density. Cells infected with rUR are shown to accumulate more Red oil O positive lipid drops than parent cells, while cells infected with hUR antisense are shown to have less Red oil O positive lipid drops. Thus, the finding shows that the expression of UR in fibroblasts plays a role in adipocyte differentiation.
Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent.
The following specific examples, which described syntheses, screenings, and biological testings of various compounds of this invention, are therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications recited herein, including patents, are hereby incorporated by reference in their entirety.
Preparation of phenylalanine conjugated-steroid derivatives
To a stirred solution of L-(or D-) phenylalanine ester hydrochloride (2 mmol) in dry DMF (10 mL) was added triethylamine (2 mmol) and the mixture was stirred at room temperature for 10 minutes. Bile acid (1 mmol) and 1-ethyl- 3-[3-dimethylaminopropyl]-carbodiimide (2 mmol) were then added and the suspension was stirred at room temperature overnight. The reaction mixture was diluted with water and ethyl acetate. The organic layer was separated and the water layer was extracted with ethyl acetate again. The combined organic layer was then washed with IN HCl, water, IN NaOH and water, and dried (MgSO).
The solvent was removed under reduced pressure to afford the steroid derivatives which were then analyzed by Thin Layer Chromatography, High Pressure Liquid
Chromatography, and/or proton-NMR.
Preparation of ethyl-3-alpha 6-alpha-dihydroxy-delta[24]-5-beta-cholestanoate
Ethyl-3-alpha,6-alpha-dihydroxy-delta[24]-5-beta-cholestanoate was prepared according to methods described above. 'H NMR: 0.63 (C18); 0.90 (C19); 1.29 (C21); 1.88 (C26); 3.61 (C3); 4.04 (C6); 4.22 (C28); 5.88 (C24).
Preparation of 3-alpha,6-alpha-dihydroxy-delta[24]-5-beta-cholestan-27-oic acid 3-Alpha;6-alpha-dihydroxy-delta{24]-5-beta- cholestan-27-oic acid was- prepared according to methods described above. "HNMR: 0.63 (C18); 0.90 (C19); 1.29 (C21); 1.88 (C26); 3.61 (C3); 4.04 (C6); 4.22 (C28); 6.85 (C24).
Preparation of ethyl-3-beta-hydroxy-delta[5,24]-cholestenoate
Ethyl-3-alpha,6-alpha-dihydroxy-delta[24}-5-beta-cholestanoate was prepared according to methods described above. "H NMR: 0.68 (C18); 0.95, - 1.00 (C19, C21); 1.83 (C26); 3.50 (C3); 4.19 (C28); 5.34 (CS); 6.74 (C24); "*’C i 15 NMR: 72.0 (C3); 121.9 (C5); 143.3 (C6); 168.8 (C27); 127.8, 141.2, 144.0 (C24,
C25).
Preparation of 3-beta-hydroxy-delta[5,24]-cholesten-27-oic acid 3-Alpha,6-alpha-dihydroxy-delta[24]-5-beta- cholestan-27-oic acid was - 20 prepared according to methods described above. 'H NMR: 0.68 (C18); 0.95, 1.00 (C19, C21); 1.83 (C26); 3.50 (C3); 4.19 (C28); 5.34 (C5); 6.79 (C24).
Yeast two-hybrid binding assay
A commercial yeast two-hybrid kit from Stratagene, HybriZAP-2.1™, was used to construct primary screening system. Four pairs of degenerated oligonucleotides were annealed, digested with EcoRI and Sall, and purified. The sequences of the four pairs of oligonucleotides are listed as follows (N represents
A,G, TorC)
WBI: 5'-GTA TCG CCG GAA TTC NNN TTG NNN NNN TTG TTG
NNN NNN TAA GTC GAC TCT AGA GCC-3' (SEQ ID NO: 2)
WB2: 5-GGC TCT AGA GTC GAC TTA NNN NNN CAA CAA NNN
NNN CAA NNN GAA TTC CGG CGA TAC-3' (SEQ ID NO: 3)
LS1: 5'-GTA TCG CCG GAA TTC ATC TTG CAC AGA TTG TTG
CAA GAA TAA GTC GAC TCT AGA GCC-3' (SEQ ID NO: 4) . LS2:5'-GGC TCT AGA GTC GAC TTA TTC TTG CAA CAA TCT
GTG CAA GAT GAA TTC CGG CGA TAC-3' (SEQID NO: 5)
WD1: 5-GTA TCG CCG GAA TTC NNN TTG NNN NNN TGG TTG
TTGNNN NNN TAA GTC GAC TCT AGA GCC-3' (SEQ ID NO: 6)
WD2: 5'-GGC TCT AGA GTC GAC TTA NNN NNN CAA CAA CCA
NNN NNN CAA NNN GAA TTC CGG CGA TAC-3' (SEQ ID NO: 7)
The purified fragments were cloned into the yeast vector pBD-GAL4 (Strategene) of the same restriction sites. The resulting plasmid pCAM/BDs . 15 expressed a fusion protein with a GAL4 DNA-binding domain (amino acid 1-147 : of Gal4) and a polypeptide of ten amino acid in length with a LXXLL (SEQ ID - NO: 8) or LXXWLL (SEQ ID NO: 9) motif. UR ligand binding domain {amino acids 141 to 443 of rUR) was generated with PCR and inserted into another yeast vector pAD-GAL4-2.1 (Strategene) with cloning site EcoRI and Xhol. The resulting plasmid, p2.1/fURLB, expressed a fusion protein containing a Gal4 ) transcription activation domain (amino acids 761-881 of Gal4) and a rUR ligand binding domain.
Plasmids pCAM/BDs and p2.1/rURLB were co-transformed into an appropriate ycast strain by using lithium acetate and polyethylenc glycol. The yeast was then grown on selective medium until the formed yeast colonies reached 2 mm. Colonies were picked and grown in selective medium for 15 hours at 30°C and B-galactosidase activities were measured with a commercial luminescence kit.
Mammalian cell transfection assay (1)
Rat UR and human RXRa gene werc cloned into a mammalian expression vector pSG5 (Strategene) by transfection with calcium phosphate and overexpressed in cultured cells. A heterogeneous promoter was constructed by inserting into the vector four tandem repeats of DR4 with sequence 5-TTC AGG
TCA CAG GAG GTC AGA GAG CT-3' (SEQ ID NO: 10) upstream to a c-fos : promoter sequence (-56-+109) which was followed by a sequence encoding luciferase. The entire construct was named DR4-fos-luc. DR4-fos-luc was then co-transfected with pSGS/UR and pSG5/hRXRa into COS-1 cells. 16-24 hours after transfection, a steroid derivative in ethanol was added to the medium until the maximum final concentration is 2 uM. The final concentration of solvent ethanol is 0.2 %. After 24-48 hours, cells that were treated with the steroid were : lysed and assayed for luciferase activity with a commercial assay kit and a - luminometer. : 15 A wide variety of compounds of this invention were tested and found to . modulate transactivation activity of UR or LXRa. For example, steroid (1) (see page 5, supra), unexpectedly increased the luciferase activity by 15-fold in comparison to absence of steroid only for UR but not LXRa; steroid (2) : unexpectedly increased the luciferase activity by 60-fold in comparison to absence of steroid only for LXRa but not UR; steroid (3), (5) or (10) can activate sv both UR or LXRa; steroid (7), (8), or (9) can antagonize UR or LXRa transactivation acitvity.
Mammalian cell transfection assay (2)
In a similar fashion to thc experiment described above, another chimeric receptor was constructed by fusing oligonucleotides encoding the ligand-binding domain of rat UR (141 to 443 amino acid residues) to a human AR gene lacking ligand-binding coding region (human AR 1 to 623 amino acid residues) and overexpressed in cultured cells. For this chimeric receptor, a reporter gene
ARE-fos-luc was constructed by inserting into the vector three tandem repeats of
Androgen Response Element (ARE) with a sequence 5'- TCG AGT CTG GTA
CAG GGT GTT CTT TTG-3' (SEQ ID NO: 11) upstream to a c-fos promoter ] sequence (-56-+109) which was followed by a sequence encoding luciferase.
Various steroid derivatives of this invention were found to modulate UR transactivation activity on DR4-fos-luc expression in the cultured cells. For example, steroid derivative (6) (see page 6, supra) unexpectedly increased the luciferase activity by 5-fold in comparison to the steroid starting material.
Mammalian cell transfection assay (3)
Human embryonic kidney 293 cells were seeded into 48-well culture - plates at 105 cells per well in DMEM supplemented with 10% (etal bovine serum. After 24 hours, cells were transfected by a calcium phosphate coprecipitation method with 250 ng of the pGL3/UREluc reporter gene which consists of three copies of AGGTCAagccAGGTCA fused to nucleotides -56 to : +109 of the human c-fos promoter in front of the firefly luciferase gene in the } plasmid basic pGL3 (Promega), 40 ng pSG5/hRXRa, 40 ng pSG5/fUR or
CMX/hLXR, 10 ng pSG5/hGripl, 0.4 ng CMV/R-luc (transfection normalization reporter, Promega) and 250 ng carrier DNA per well. Alternatively, 500 ng of the pGL2/7aluc reporter gene which consists of a single copy of nucleotides -101 to 49 of the rat 7a-hydroxylase gene fused to the SV40 promoter in front of the firefly luciferase gene in the plasmid basic pGL2 (Promega) was used instead of pGL3/UREluc. This reporter does not have response elements for COUP-TFII or
HNF4. In some experiments, 500 ng ot the human 7a-hydroxylase gene reporter,
PH/hCYP7A-135, which consists of a single copy of nucleotides -135 to +24 of the human CYP7A gene fused to the firefly luciferase gene in the plamid basic pGL3 (Promega), was used instead of pGL2/7aluc. After another 12-24 hours, cells were washed with PBS and refed with DMEM supplemented with 4% delipidated fetal bovine serum. Steroid derivatives dissolved in ethanol were added in duplicate to the medium so that the final concentration of alcohol was 0.2%. After 24-48 hours, cells were harvested and luciferase activity was measured with a commercial kit (Promega Dual luciferase IT) on a Monolight luminometer (Beckton Dickenson). Both LXR and UR form heterodimers with
RXR for gene transactivation. The ligand for RXR, 9-cis retinoic acid, is known to activate the LXR/RXR heterodimer but addition of 9-cis retinoic acid to transactivation assays did net change the-potency of either Aor -6a-hydroxy steroids for activation of LXR or UR (data not shown). The expression of endogenous LXR and UR (and TR which also binds to a DR4 response element) were apparently low since reporter activation was low in the absence of added expression vectors for LXR or UR. Reporter activation was also low when the
DR4 response-element was replaced with a glucocorticoid receptor response : element. Each experiment was repeated as least twice to demonstrate reproducability. Relative light units were about 2 x 10’ for pGL3/UREluc, 1 x : 15 10° for pGL2/7aluc, 5 x 10* for PH/hCYP7A-135 and 5 x 10° for CM V/R-luc.
Purity of synthesized steroid derivatives was verified by thin layer chromatography and structures were confirmed using proton and C"° magnetic resonance spectrometry. 3-Oxo-6a-hydroxy-5f3-cholanoic acid methyl ester, 3a.,60-dihydroxy-3B-cholanoic acid methyl ester, and 3a,6a,7a-trihydroxy-5p- : 20 cholanoic acid methyl ester were found to be as potent as 3f3-hydroxy-A>- cholanoic acid methyl ester as activators for LXR, with EDsy's of about 150 nM.
Loss of activity was seen when the 6a-hydroxy group was changed to a 6 configuration. In contrast to activity with LXR, 3B-hydroxy-A°- cholanoic acid methyl ester (EDsp of 130 nM) was more active than 3-oxo-6a-hydroxy- cholanoic acid methyl ester (EDs of 550 nM) and 3a,6a-dihydroxy-cholanoic acid methyl ester (EDso of 500 nM) for UR activation.
Using the same assay, EDsy’s of 6a-hydroxylated steroids with 24-keto side chains include free and conjugated 3a,6a-dihydroxy-35f-cholanoic acid and 3a,60,7a-trihydroxy-58-cholanoic acid were determined. These steroid
Claims (80)
1. A compound of the following formula: R12 RT 17 RY i R16 rR? CIT INE R? ip R’ R* R¥ R® wherein Ris hydrogen, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -
: S0;-, -0-80;-, -S0,-0-, -0-S03-, -S03-0-, -CO-, -CO-0-, -O-CO-, -CO-NH-, - CO-N(alkyl)-, -NH-CO-, or -N(alky1)-CO-, and further optionally substituted : with hydroxy, halo, amino, carboxyl, sulfonic acid, or —O-sulfonic acid;
- each of R', R%, R*, R*, R%, R",R", R'%, R"*| R'®, and R'", independently,
" 10 is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -S80>-, - 0-S0;-, -80,-0-, -0-803-, -S03-0-, -CO-, -CO-0-, -0-CO-, -CO-NH-, -CO-
N(alkyl)-, -NH-CO-, or -N(alkyl}-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or ~O-sulfonic acid, each of R’, RS, rR’, RY, RY, and R™, independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; R'7 is -X-Y-Z, in which X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming a : cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R'7 are bonded; Y is -CO-, -SO-, -S0;-, -0-S0;-, -SO,-0-, -0-S0;-, -S03-0-, -CO-O-, - 0-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, -N(alky1)-CO-, or a bond; and Z is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio; or is -CH(A)-B with A being a side chain of an amino acid, and B being hydrogen, - NR?R®, or -COOR® wherein cach of R?% R® and RS, independently, is hydrogen or alkyl; and nis 0, 1,or2; provided that when Z is substituted with carboxyl or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl- 15, -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl, or is alkenyl; or a salt thereof.
2. The compound of claim 1, wherein n is 0.
3. The compound of claim 1, wherein R® is amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl; R®is hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl; and each of R® and RS, independently, is in the a- configuration.
4. The compound of claim 1, wherein R® is hydrogen and is in the B- configuration.
5. The compound of claim 1, wherein R® is oxo; each of R, R%L, R* R*,R% R’, R', R12 RY, R'S and R'7, independently, is hydrogen, hydroxy, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl.
6. The compound of claim 5, wherein each of R', R?, R*, R*, R®, R’, R'!, R"?, R" R'S and rR", independently, is hydrogen, hydroxy, or oxo; and each of R®, R: RY RY, RY, and R", independently, is hydrogen or hydroxy; or a salt thereof.
7. The compound of claim 6, wherein X is a bond or alkyl.
8. The compound of claim 7, wherein Y is -C(=0)-NH- or -NH-C(=0)-; and Z is -CH(A)-B with A being a side chain of Tyr or Phe, and B being -NR*R® or - COOR*
- 9. The compound of claim 1, wherein X is a bond or alkyl.
10. The compound of claim 9, wherein Y is -C(=0)-NH- or -NH-C(=0)-; and Z is -CH(A)-B with A being a side chain of Tyr or Phe, and B being -NR*R" or - COOR®
11. The compound of claim 6, wherein Y is -CO-, -O-S0O,-, -SO,-O-, -0-SOs-, - SO;-0-, -CO-NH-, -NH-CO-, or a bond.
12. The compound of claim 11, wherein Z is alkyl, alkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, halo, sulfonic acid, carboxyl, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl; or is -CH(A)-B.
13. The compound of claim 1, wherein Z. is alkyl or aryl, each of which being optionally substituted with hydroxy; or is -CH(A)-B with A being an amino acid side chain having an aromatic moiety, and B being -NR’R®, or -COOR®.
14. The compound of claim 1, wherein R'? contains a straight chain having 6-20 chain atoms.
15. The compound of claim 14, wherein R'” contains a straight chain having 8-16 chain atoms.
16. The compound of claim 1, wherein X is ~CH(CH3)-CH,-, Y is a bond, and Z is ~CH;-CH=C(R")(CH;) with R’ being hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio.
17. The compound of claim 1, wherein said compound is: COOMe CH.CI HN— 1) 0 (21) 0 H o : HOH ~ re lo] lo; H 0 : o, ,—COOH H 6H NH CF3 HN— (6) lo] x or (23) o H 0 H H OH
18. A compound of the following formula: 17 : R12 R R17 13 11 R R R' 6 R'
R . R3 R15 R’ 4 x 3 7 R r 5 R , 6 . RY R* R wherein eachof R',R%, R’, RY, R*,R%, R", R",R', R"*, R", and R", independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, - O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S- ,-80-,-80,-, -0-80,-, -S0,-0-, -0-S0O3-, -§03-0-, -CO-, -CO-0-, -0-CO-, - CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; each of R® s RY, R’, rR" R" , and RM, independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; R'is -X-Y-Z, in which X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R"7 are ] bonded; Y is -CO-, -SO-, -SO;-, -O-50;-, -S§0,-0-, -O-503-, -§0;-0-, -CO-0-, - O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond; and Z is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio; or is -CH(A)-B with A being an amino acid side chain containing an aromatic moiety, and B being hydrogen, -NR*R®, or -COOR® wherein each of R?, R, and R’, independently, is hydrogen or alkyl; and nis0, 1,012; provided that when Z is substituted with carboxy! or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either X is -NH-alkyl-, -NH-alkeny!-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl- , -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl, or is alkenyl;
or a salt thereof.
19. The compound of claim 18, wherein n is 0.
20. The compound of claim 18, wherein each of R® and R®, independently, is hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl, and is in the a-configuration. or
21. The compound of claim 18, wherein R® is hydrogen and is in the p- configuration.
22. The compound of claim 18, wherein each of R', R>, R>, R*, R* R%, R", R'", R'?, RY R'®, and R'7, independently, is hydrogen, hydroxy, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl.
23. The compound of claim 22, wherein each of R', R?, R*, R* R* R’, R", R'!, R'2, RY RS and R'7, independently, is hydrogen, hydroxy, or oxo; and each : of R> RE, rR’ R!® R" and RY, independently, is hydrogen or hydroxy.
24. The compound of claim 23, wherein X is a bond or alkyl. 15
25. The compound of claim 24, wherein Y is -C(=0)-NH- or -NH-C(=0)-; and Z is -CH(A)-B with A being a side chain of Tyr or Phe, and B being -NR°R" or - COOR®
26. The compound of claim 18, wherein X is a bond or alkyl.
27. The compound of claim 26, wherein Y is ~C(=0)-NH- or -NH-C(=0)-; and Z is -CH(A)-B with A being a side chain of Tyr or Phe, and B being -NR*R" or - COOR®
28. The compound of claim 18, wherein Y is -CO-, -O-SO;-, -80,-0O-, -O-SOs-, - S03-0-, -CO-NH-, -NH-CO-, or a bond.
29. The compound of claim 28, wherein Z is alkyl, alkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, halo, sulfonic acid, carboxyl, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl; or is -CH(A)-B. 10
30. The compound of claim 18, wherein Z is alkyl or aryl, each of which being optionally substituted with hydroxy; or is -CH(A)-B with A being an amino acid side chain having an aromatic moiety, and B being -NR°R", or -COOR®.
31. The compound of claim 18, wherein R"? contains a straight chain having 6-20 chain atoms. 15
32. The compound of claim 31, wherein R'” contains a straight chain having 8-16 chain atoms.
33. The compound of claim 18, wherein X is ~-CH(CH;)-CH,-, Y is a bond, and Z is -CH,-CH=C(R’)(CH3;) with R’ being hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio. )
34. The compound of claim 18, wherein said compound is: - VO [s) (0) % COOMe (10) HO” [o) Ho p= H OH ° 3 " ero o (1h) HO™ Y H oH o] L Ho : y © H oH (8) s ° 2) ns OH ” HO . H HO” y i 7 H oH on LP in FR WY; O ©) ~~ I~ CH (17) HO H (28) z HO" : H bh HO : OH OH F OH 7% J a (29) { (30) or an HO H HO Y HO : OH oH OH
35. A compound of the following formula:
R12 rR R17
1 R R R’ 6 R1 R1 0 } RZ 15 C= ) R n 3 7 R RS R R* RY RS wherein each of R',R%, R’, R*, R*,R®, R’,R"", R'2 R"*, R!®, and R", . 5 independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -
O-sulfonic acid, or alkyl optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-,
-80;-, -0-80;-, -80;-0-, -0-S0;-, -S03-0-, -CO-, -CO-0-, -0O-CO-, -CO-NH-, -
CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid;
each of R>, RS, R?, RO, R"3, and R', independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino;
R'7 is -X-Y-Z, in which X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'%and R' are bonded; Y is -CO-, - SO-,-80;-, -0-SO;-, -S0;-0-, -O-5803-, -S03-0-, -CO-0O-, -0-CO-, -CO-NH-, - CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond; and Z is alkyl, alkenyl, atkynyl; cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio; or is -CH(A)-B with A being a side chain of an amino acid, and B being hydrogen, -NR?R®, or -COOR® wherein each of R?, RP", and RS, independently, is hydrogen or alkyl; and nis0, 1, o0r2; = 15 provided that when Z is substituted with carboxyl or alkyloxycarbonyl, Y a is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl- , -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, ‘ sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl], or is alkenyl; and further provided that at least one of R? and R*, R* and R%, R” and R%, R'? and R", and R"* and R'¢, independently, is deleted to form a double bond; or a salt thereof.
36. The compound of claim 35, wherein n 1s 0.
37. The compound of claim 35, wherein R’is hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl, and is in the a-configuration.
38. The compound of claim 35, wherein each of R', RR? RY, RY RS, RR", R'%, RR" and R'7, independently, is hydrogen, hydroxy, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl.
39. The compound of claim 38, wherein each of R', R?, R?>, R*, R*, R%, R", R"", R'%Z, R¥, RS and R'7, independently, is hydrogen, hydroxy, or oxo; and cach of R®, R® R’ R'" R" and R", independently, 1s hydrogen or hydroxy.
40. The compound of claim 39, wherein X is a bond or alkyl.
41. The compound of claim 40, wherein Y is -C(=0)-NH- or -NH-C(=0)-; and Z is -CH(A)-B with A being a side chain of Tyr or Phe, and B being -NR*R" or - COOR®
42. The compound of claim 35, wherein X is a bond or alkyl.
43. The compound of claim 35, wherein Y is -CO-, -O-SO,-, -S0,-0O-, -0-S0;3-, - S0;-0-, -CO-NH-, -NH-CO-, or a bond.
44. The compound of claim 35, wherein Z is alkyl or aryl, each of which being optionally substituted with hydroxy; or is -CH(A)-B with A being an amino acid side chain having an aromatic moiety, and B being -NR°R®, or -COOR®.
45. The compound of claim 35, wherein R'? contains a straight chain having 6-20 chain atoms.
46. The compound of claim 45, wherein R'? contains a straight chain having 8-16 chain atoms.
'
47. The compound of claim 35, wherein X 1s -CH(CH3)-CH;-, Y is a bond, and Z is —~CH,-CH=C(R’)(CH3) with R’ being hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio. - --
48. The compound of claim 35, wherein said-compound is: : OH o ~~ £1 ©) ---OH Oo
49. A compound of the following formula:
17 . R12 R R' 7 13 RY R R16 R! R’ 0 . i RZ p 15 14 R R n 3 7 R RS R , 6 0 RY RY R wherein each of R', R%, R’,R%, R*,R% R’,R'",R'4, R”, R'’, and R7, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, - O-sulfonic acid, or alkyl optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO;-, -0-S0;-, -S0,-0-, -0-80s-, -S05-0-, -CO-, -C0O-0-, -O-CO-, -CO-NH-, -
CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid, each of RS, RS, rR’, R'C R'3, and R", independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; R'is -X-Y-Z, in which X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming a cyclic moiety with R' and the 2 ring carbon atoms to which R'® and R'” are bonded; Y is -CO-, - S0-, -80;-, -0-80;-, -80,-0-, -0-80;-, -803-0-, -CO-0-, -O-CO-, -CO-NH-, - CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond; and Z is alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio; or is -CH(A)-B with A being a side chain of an amino acid, and B being hydrogen, -NR°R®, or -COOR® wherein each of R%, R®, and RF, independently, is hydrogen or alkyl; and nis0,1,or2; provided that when Z is substituted with carboxyl or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl- , -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl, or is alkenyl; and further provided that at least one of R> and R%, R*and R® ,R’% and R% R’ and R®, Rand R" and R" and R'S, independently, is deleted to form a double bond; or a salt thereof.
50. The compound of claim 49, wherein n is 0.
51. The compound of claim 49, wherein R? is hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl, and is in the «-configuration.
52. The compound of claim 49, wherein each of RY RZ, R}, RY RY, R®, R’, R', RZ, R"%,R' andR"7, independently, is hydrogen, hydroxy, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl.
53. The compound of claim 52, wherein cach of R', RR? RY, RY, R®, R’, R", rR"? RY, R'®, and R'7, independently, is hydrogen, hydroxy, or oxo; and each of R°, R%, R%, R'%, R"?, and R", independently, is hydrogen or hydroxy.
54. The compound of claim 53, wherein X is a bond or alkyl. 10
55. The compound of claim 54, wherein Y is -C(=0)-NH- or -NH-C(=0)-; and Z - is -CH(A)-B with A being a side chain of Tyr or Phe, and B being -NR°R® or - COOR°®
56. The compound of claim 49, wherein X is a bond or alkyl. : .
57. The compound of claim 56, wherein Y is -C(=0)-NH- or -NH-C(=0)-; and Z is -CH(A)-B with A being a side chain of Tyr or Phe, and B being -NR*R® or - COOR°
58. The compound of claim 49, wherein Y is -CO-, -O-80;-, -SO;-O-, -0-S0;-, - S0;-0-, -CO-NH-, -NH-CO-, or a bond.
59. The compound of claim 49, wherein R'” contains a straight chain having 6-20 chain atoms.
. ) 60. The compound of claim 59, wherein R'7 contains a straight chain having 8-16 chain atoms.
61. The compound of claim 49, wherein X is -CH(CH:)-CH,-, Y is a bond, and Z is -CH,-CH=C(R’)(CH;) with R” being hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio.
62. The compound of claim 49, wherein said compound is:
@ PCT/US00/11243 \ N— , @
0 . HO ’ / CF, - (13) (eo HO480O HO ee : N g
AS . HO HO,S0 oo or VERN % (24) (20) (25) HO HO HO F OH / / or (26) (27 HO HO
63. Use of a compound of the following formula: -53- AMENDED SHEET
® PCT/US00/11243 oo : R12 RY p17 : R11 R'3 R16 ) Rr! uLlr BENG 6 Ga Co | RA 1; R7 | : oo oo Rtg RS wherein : E Ris hydrogen, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic . _ "acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, - oo - 5 SO, -0-SOs-, -503-0-, -0-SOy-, -S03-O-, -CO-, -CO-O-, -0-CO-, -CO-NH-, - } - CO-N(alkyl)-, -NH-CO-, or -N(alky})-CO-, and further optionally substinuted : ‘with hydroxy, halo, amino, carboxyl, sulfonic acid, or —Q-sulfonic acid; : 3 each of R', R%, R* RY RS, rR’, RR"? R" R'® and R'7, independently, : ) is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, . : oo 10 or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO»-, - B © 0-80;-, -80;-0-, -0-80;-, -§03-0-, -CO-, -CO-0-, -0-CO-, -CO-NH-, -CO- | : . . N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with oo : - hydroxy, halo, amino, carboxyl, sulfonic acid, or —O-sulfonic acid; -54 - * AMENDED SHEET -
LC ) PCT/US00/11243 each of R*, R}, R%. R', R", and R", independently, is hydrogen, alkyl, ~ haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino;
R'7 is -X-Y-Z, in which X is a bond, or alkyl or alkenyl, optionally inserted with -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming.a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R' are bonded; Y is -CO-, -SO-, -S0--, -0-S0O;-, -SO;-0-, -0-50;-, -50;-0-, -CO-0-, - 0-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond: and Z is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl. cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl. aralkyl, or heteroaralkyl. and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylamimnocarbonyl, alkylcarbonylamino, alkylcarbonyl. alkylsulfinyl, alkylsulfonyl. or alkylthio: or 1s -CH(A)-B with A being a side chain of an amino acid, and B being hydrogen, - NR°R®, or -COOR® wherein each of R® R", and R®, independently, is hydrogen or alkyl; and «
nis 0, 1,or2; :
provided that when Z is substituted with carboxyl or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either X is -NH-alkyl-, -NH-alkenyli-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyi- , -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is substituted with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl, or is alkenyl; or a salt thereof,
in the manufacture of a medicament for treating a UR- or a LXR- mediated disorder. -55- AMENDED SHEET
¢ PCT/US00/11243
64. Use according to claim 63, wherein said compound is AN COOMe } CH,CI Hn" th Oo (an 0 a] . o H OH / (5) (22) oO H o 0, ,/—COOH H OH NH CF; HN— (6) « 0 23 Oo or 23)
H . [e) y H OH
65. Use of a compound of the following formula: - 56 - AMENDED SHEET
PY ~ PCT/US00/11243 - : R'2 RY p17 R'! R™ R16 oo R10 - : RY 15 Ee R3 1s ~Y : R* RY R® oo : wherein EE oo each of R', R%, R*, RY, R*, RR", R" R'", RR", and R'", : oo : independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, - O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl}-, -O-, -S- . ,-S0-,-§0;-, -0-50z-, -803-0-, -0-80s-, -§03-0-, -CO-, -CO-0-, -0-CO-, - - : CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally : . substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; ’ 10 cach of R® s RS, rR’, R'C RY, and rR", independently, is hydrogen, alkyl, Co haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; R'7 is -X-Y-Z, in which X is a bond, or alkyl or alkenyl, optionally oo : inserted with -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R'” are bonded; Y 1s -CO-, -SO-, -S0O3-, -0-50;-, -S0,-O-, -0-SOs-, -80;3-0-, -CO-0-, - : " 0-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond; and Z is : alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is substituted : - : with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, Co 20 alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, + alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkylthio; or is -CH(A)-B with A° -57 - oo | * AMENDED SHEET | :
C3 PCT/US00/11243 being an amino acid side chain containing an aromatic moiety, and B being hydrogen. -NRR®, or -COOR® wherein each of R®, R®, and R", independently. is hydrogen or alkyl; and nis 0,1, or 2; provided that when Z is substituted with carboxyl or alkvloxycarbonyl, Y - is a bond and either X or Z contains at least one double bond, and that when Y is a bond, either X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl- , -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z is subsututed with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsuifonyl, or is alkenyl; : or a salt thereof, in the manufacture of a medicament for treating a UR- or a LXR- mediated disorder.
66. Use according to claim 635, wherein said compound is: - 58 - AMENDED SHEET e PCT/US00/11243 A. = 0 (2) { OOMe : » (10) . ’ HO o : io . H Y . O— H OH . . . : | : ° a ass . Ro Y : . : Hon . o - - . : HO’ H . 0 ae } 8) 5 : 9% ay - OH H Ho a A on . - oH - ah } ot
On . 0 0 . oo OH | (17) : HO I~ (28) oo HO Y H bu HO : . on . So aa F oH a : Be] . :
@ . HO” H HO v | HO T OH ] én OH .
59. oo "AMENDED SHEET
@- PCT/US00/11243
67. Use of a compound of the following formula: R12 RY 17 13 R'! R R16 R' R2 R R15 R14 . 3 7 R RS R 4 ' RS R Rr Rr? wherein each of R, R®. R’, R*. R*. R% R", R',R" R',R", and R'7, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, - O-sulfonic acid, or alkyl optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO2-, -0-S03-, -S0,-0-, -0-803-, -S0;-0-, -CO-, -CO-0-, -0O-CO-, -CO-NH-, - CO-N(alky])-, -NH-CO-, or -N(alkyl}-CO-, and further optionally substituted . with hydroxy, halo, amino. carboxyl, sulfonic acid, or -O-sulfonic acid; each of R*, R® R? R'®, R", and R'4, independently, is hydrogen, alkyl. haloalkyl, hydroxyalkyl, alkoxy. hydroxy, or amino: R'is -X-Y-Z, in which X is a bond, or alkyl or alkenyl, optionally inserted with ‘ - 60 - AMENDED SHEET
® PCT/US00/11243 -NH-, -N(alkyl)-, -O-, or -S-, and further optionally forming a cyclic moiety with R'® and the 2 ring carbon atoms to which R'® and R'7 are bonded; Y is -CO-, - SO-, -S03-, -0-S03-, -S0,-0-, -0-S0;-, -S03-0-, -C0O-0-, -0-CO-, -CO-NH-, - CO-N(alkyl)-, -NH-CO-, -N(alkyl)-CO-, or a bond; and Z is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, amino, halo, sulfonic acid, -O-sulfonic acid, carboxyl, oxo, alkyloxycarbonyl, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, alkylsulfonyl, or alkyithio; or is -CH(A)-B with A being a side chain of an amino acid, and B being hydrogen, -NR*R®, or -COOR® wherein each of R?, R®, and Rf, independently, is hydrogen or alkyl; and nis0, |, or 2; provided that when Z is substituted with carboxyl or alkyloxycarbonyl, Y is a bond and either X or Z contains at least one double bond, and that when Y 1s a bond, either X is -NH-alkyl-, -NH-alkenyl-, -N(alkyl)-alkyl-, -N(alkyl)-alkenyl- , -O-alkyl-, -O-alkenyl-, -S-alkyl-, or -S-alkenyl-; or Z 1s substituted with halo, sulfonic acid, -O-sulfonic acid, alkylsulfinyl, or alkylsulfonyl], or is alkenyl; and further provided that at least one of R* and R*, R* and R®, R* and R’, R” and R?, R'? and RY, and R" and R'®, independently, 1s deleted to form a double bond; or a salt thereof, in the manufacture of a medicament for treating a UR- or a LXR- mediated disorder.
68. Use according to claim 67, wherein said compound is: -61- AMENDED SHEET
CY ~ . ~ PCT/US00/11243 E Al Co oo o No 2 ~~ Da .-OK | a3 CC @ oo . o So HO™ HO od OOH o ONH, : : a9 : . | N 0s) “ N | HOsS0 7 -
wo . : : o ee oo OOH CN F us) ASR oo | HO350 ad . i y Ee < J. Te TT oY oo - : 0 25) :
a @. 7 } ¢ | . @n © HO " " | | N ) | -62 - B AMENDED SHEET o PCT/US00/11243
69. A substance or composition for use in a method for treating a UR- or a LXR- mediated disorder, said substance or composition comprising a compound of the formula defined in claim 63, and said method comprising administering an effective ) amount of said substance or composition.
70. A substance or composition for use in a method of treatment according to claim 69, wherein said compound is as defined in claim 64.
71. A substance or composition for use in a method of treating a UR- or LXR- mediated disorder, said substance or composition comprising a compound of the formula defined in claim 65, and said method comprising administering an effective amount of said substance or composition.
72. A substance or composition for use in a method of treatment according to claim 71, wherein said compound is as defined in claim 66.
73. A substance or composition for use in a method of treating a UR- or a LXR- mediated disorder, said substance or composition comprising a compound of the formula defined in claim 67, and said method comprising administering an effective amount of said substance or composition.
74. A substance or composition for use in a method of treatment according to claim 73, wherein said compound is as defined in claim 68.
75. A pharmaceutical composition comprising a compound of the formula as defined in any one of claims 63, 65, or 67, and a pharmaceutically acceptable carrier.
76. A compound according to any one of claims 1 - 62, substantially as herein described and illustrated.
77. Use according to any one of claims 63 - 68, substantially as herein described and illustrated. -63- AMENDED SHEET
@ PCT/US00/11243
78. A substance or composition for use in a method of treatment according to any one of claims 69 - 74, substantially as herein described and illustrated.
79. A composition according to claim 75, substantially as herein described and illustrated.
80. A new compound, a new use of a compound as defined in any one of claims 63 - 68, a new composition, or a substance or composition for a new use in a method of treatment, substantially as herein described. - 64 - AMENDED SHEET .
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13172899P | 1999-04-30 | 1999-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200109793B true ZA200109793B (en) | 2003-02-28 |
Family
ID=27804498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200109793A ZA200109793B (en) | 1999-04-30 | 2001-11-28 | Steroid derivatives. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200109793B (en) |
-
2001
- 2001-11-28 ZA ZA200109793A patent/ZA200109793B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6645955B1 (en) | 3,6-dihydroxy-24-amidyl steroid derivatives | |
ES2847002T3 (en) | 11-hydroxyl-6-substituted derivatives of bile acids and amino acid conjugates thereof as modulators of the farnesoid X receptor | |
Cushman et al. | Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth | |
US7858608B2 (en) | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions | |
CA2922021C (en) | A method for treating diabetes | |
AU2007265457B2 (en) | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions | |
US5512558A (en) | Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments | |
CZ113594A3 (en) | Tetrazole derivatives of bile acids, process of their preparation and use of said compounds as medicaments | |
US20060025393A1 (en) | Steroid derivatives | |
US20070032464A1 (en) | Methods of treating cancers | |
US20020119958A1 (en) | Therapeutic agent for hyperlipidemia | |
Salomatina et al. | Deoxycholic acid as a molecular scaffold for tyrosyl-DNA phosphodiesterase 1 inhibition: A synthesis, structure–activity relationship and molecular modeling study | |
Ju et al. | Design and synthesis of novel mitochondria-targeted CDDO derivatives as potential anti-cancer agents | |
CA2564963A1 (en) | Steroid prodrugs with androgenic effect | |
Dal Prà et al. | Targeting RORs nuclear receptors by novel synthetic steroidal inverse agonists for autoimmune disorders | |
Stefela et al. | (E)-7-Ethylidene-lithocholic acid (7-ELCA) is a potent dual farnesoid X receptor (FXR) antagonist and GPBAR1 agonist inhibiting FXR-induced gene expression in hepatocytes and stimulating glucagon-like peptide-1 secretion from enteroendocrine cells | |
Liu et al. | Design, synthesis, and structure–activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis | |
US20170233431A1 (en) | Bile acid derivatives and methods for synthesis and use | |
ZA200109793B (en) | Steroid derivatives. | |
Veleiro et al. | 6, 19-Sulfur-bridged progesterone analogues with antiimmunosuppressive activity | |
EP3658566B1 (en) | Side-chain modified ergosterol and stigmasterol derivatives as liver x receptor modulators | |
KR20090101914A (en) | 6-alkoxyalkyl estradiol derivatives and methods of use | |
NZ714082B2 (en) | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators | |
KR20070020454A (en) | Steroid Prodrugs with Androgenic Effect |